CREM Co Labs develops and evaluates biofertilizer consortia comprising nitrogen-fixing, phosphate-solubilizing, and plant-growth-promoting bacteria. These formulations improve soil health, nutrient uptake, and yield in greenhouse crops such as lettuce, cucumber, and tobacco. The products are tested under controlled and field conditions and developed in collaboration with Dimeh Inc., targeting sustainable agriculture and reduced dependency on chemical fertilizers.

CREM Co Labs is developing a synthetic biology–based bacteria-mediated cancer therapy derived from foundational research on tumor-targeting Clostridium sporogenes. The technology uses genetically engineered, selectively aerotolerant Clostridium strains that colonize the hypoxic and viable rims of solid tumors without affecting healthy tissue.

The platform integrates:

Aerotolerance enzyme expression to enable growth in semi-aerobic tumor regions.

Synthetic quorum-sensing circuits to control gene expression only within tumor environments.

Payload delivery systems for on-site production of therapeutic or immunostimulatory molecules.

This approach overcomes limitations of classical anaerobic therapies by preventing tumor regrowth from viable rims, enhancing tumor specificity, and minimizing systemic toxicity. Ongoing work at CREM Co Labs focuses on strain optimization, safety mechanisms, and translational evaluation in preclinical models (zebrafish and mammalian).

REM Co Labs’ chemical analysis facility provides testing for raw materials, finished products, and environmental samples. Capabilities include LC-MS/MS, GC-MS, GC-FID, Atomic Absorption, and HPLC. Services cover active ingredient quantification, residual solvent analysis, preservative determination, and formulation stability. The lab also conducts microbial volatile organic compound (mVOC) analysis to assess product emissions and environmental safety.

CREM Co Labs provides a comprehensive suite of microbiological tests for food, beverage, and NHP industries. Services include pathogen detection (Listeria, Salmonella, E. coli, Staphylococcus), spoilage organism testing, and shelf-life studies. All tests are conducted under ISO/IEC 17025 accreditation, ensuring regulatory compliance and accuracy. Specialized assays include USP 60, 61, 62, 2021, and 2022 for product quality and microbial contamination control.

CREM Co Labs operates one of the few room-scale aerobiology chambers in North America capable of studying airborne pathogen behavior under controlled conditions. Studies include air sanitizer efficacy, aerosol survival kinetics, and mVOC emission profiling. Technologies evaluated include far-UVC, plasma ionization, hydrogen peroxide vapor, and glycol vapors. CREM’s aerobiology testing is used by leading global companies to validate air purification and disinfection systems under EPA and Health Canada frameworks.

CREM’s zebrafish facility offers in-vivo evaluation of pharmaceutical, antiseptic, and natural compounds. Tests include acute toxicity, neurobehavioral response, cardiac rhythm monitoring, and organ development endpoints. The platform is ideal for early-stage screening, comparative safety studies, and mechanism-of-action research aligned with OECD and ICH guidance.

CREM Co Labs is an internationally recognized facility for GLP-compliant efficacy testing of disinfectants, antiseptics, and sanitizers. Testing follows AOAC, ASTM, and EN standards to evaluate bactericidal, fungicidal, sporicidal, mycobactericidal, and virucidal activity. Studies support EPA and Health Canada registration of hospital-grade and broad-spectrum disinfectants, wipes, and sprays. Services also include stability, neutralization validation, and claim substantiation for new product development.